Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use

US11021535B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• Sanaria Inc. · US

Inventors

• Robert Seder · Chevy Chase Section Five, US
• Neville Kisalu · Bethesda, US
• Azza Idris · Bethesda, US
• Barbara Flynn · Bethesda, US
• Stephen L. Hoffman · Gaithersburg, US

Key dates

• Filing date: Feb 12, 2018
• Grant date: Jun 1, 2021
• Expiry date: Feb 12, 2038

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein and neutralize P. falciparum are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.